Related Experiment Videos
Thiazide diuretics in renal hypercalciuria
Insights
Hydrochlorothiazide and amiloride treatment helped most renal hypercalciuric patients. However, developing hypercalcaemia during treatment may identify non-suppressible hyperparathyroidism, aiding diagnosis.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Renal hypercalciuria is a risk factor for kidney stone formation.
- Normocalcaemic hyperparathyroidism can be challenging to diagnose.
- Hydrochlorothiazide and amiloride are commonly used to manage hypercalciuria.
Purpose of the Study:
- To evaluate the efficacy of hydrochlorothiazide and amiloride in reducing stone formation and parathyroid hyperactivity.
- To investigate the diagnostic utility of hydrochlorothiazide/amiloride-induced hypercalcaemia in identifying specific patient subgroups.
Main Methods:
- A cohort of 46 renal hypercalciuric normocalcaemic patients received hydrochlorothiazide (50mg/day) and amiloride (5 mg/day).
- Treatment outcomes included changes in urinary calcium excretion and parathyroid hormone levels.
- Patients who developed hypercalcaemia were further assessed, with some undergoing parathyroidectomy.
Main Results:
- 41 out of 46 patients showed reduced hypercalciuria and suppressed parathyroid activity.
- Five patients did not exhibit parathyroid suppression and developed hypercalcaemia.
- Parathyroidectomy in four of these five patients normalized biochemical markers of hyperparathyroidism.
Conclusions:
- Hydrochlorothiazide and amiloride are effective in managing hypercalciuria and parathyroid hyperactivity in most patients.
- The development of hypercalcaemia during this treatment can serve as a diagnostic marker for pharmacologically resistant hyperparathyroidism.
- This finding aids in identifying patients with non-suppressible normocalcaemic hyperparathyroidism.
Abstract:
Forty-six renal hypercalciuric normocalcaemic patients were treated with hydrochlorothiazide (50mg/day) and amiloride (5 mg/day), both to reduce new stone formation and to suppress parathyroid hyperfunction. A reduction of hypercalciuria and suppression of parathyroid hyperactivity were observed in 41 patients, while in the other five patients no evidence of parathyroid suppression was found and hypercalcaemia developed. Four of five patients underwent parathyroidectomy which was followed by a normalisation of biochemical signs of hyperparathyroidism. These results suggest that the appearance of hypercalcaemia in renal hypercalciuric patients during hydrochlorothiazide/amiloride treatment may be of diagnostic value in unmasking pharmacologically non-suppressible normocalcaemic hyperparathyroidism.